Krystal Biotech Inc (KRYS) — Cash Flow-to-Debt Ratio
Krystal Biotech Inc (KRYS) has a Cash Flow-to-Debt Ratio of 0.67x as of March 2026, meaning its operating cash flow of $80.38 Million could theoretically repay 1% of its total liabilities ($120.24 Million) in one year. See Krystal Biotech Inc (KRYS) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Krystal Biotech Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Krystal Biotech Inc across 10 annual periods. Also explore Krystal Biotech Inc net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Krystal Biotech Inc (2016–2025)
Year-by-year debt coverage analysis for Krystal Biotech Inc. For market capitalisation and broader financial context, see market value of Krystal Biotech Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 1.76x | $200.87 Million | $114.23 Million | ▲ +55.9% |
| 2024 | 1.13x | $123.42 Million | $109.46 Million | ▲ +150.4% |
| 2023 | -2.24x | $-88.80 Million | $39.71 Million | ▲ +19.5% |
| 2022 | -2.78x | $-100.57 Million | $36.22 Million | ▼ -89.5% |
| 2021 | -1.47x | $-47.94 Million | $32.72 Million | ▼ -5.4% |
| 2020 | -1.39x | $-26.08 Million | $18.76 Million | ▲ +54.6% |
| 2019 | -3.06x | $-18.71 Million | $6.11 Million | ▲ +6.3% |
| 2018 | -3.27x | $-9.45 Million | $2.89 Million | ▲ +46.2% |
| 2017 | -6.08x | $-3.89 Million | $640.00K | ▼ -777.6% |
| 2016 | -0.69x | $-1.31 Million | $1.89 Million | — |